Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)

Leukemia

Volumn 18, Issue 1, 2004, Pages 133-138

  Palumbo, A ^a   Bringhen, S ^a   Bertola, A ^a   Cavallo, F ^a   Falco, P ^a   Massaia, M ^a,b   Bruno, B ^a   Rus, C ^c   Barbui, A ^d   Caravita, T ^e   Musto, P ^f   Pescota, N ^g   Rossini, F ^h   Vignetti, M ⁱ   Boccadoro, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Center for Molecular Biotechnology   (Italy)

^c Ospedale Evangelico Valdese   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e Division of Surgery   (Italy)

^f IRCCS   (Italy)

^g Ospedale Lorenz B:Ohler   (Italy)

^h H S Gerardo   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

Author keywords

Dose intensive; Melphalan; Myelomatransplantation

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 10744225243     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403196     Document Type: Article

References (28)

1. Alegre A, Díaz-Mediavilla J, San Miguel J, Martinez R, Garcia Larana J, Sureda A et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Bone Marrow Transplant 1998; 21: 133-140.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
3. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
4. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
5. Bjorkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
6. Gianni AM, Tarella C, Bregni M, Siena S, Lombardi F, Gandola L et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994; 12: 503-509.
7. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly dignosed multiple myeloma: a population-based study. Blood 2000; 95: 7-11.
8. Moreau P, Misbahi R, Milpied N, Morineau N, Mahe B, Vigier M et al. Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma. Leukemia 2002; 16: 1838-1843.
9. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838-847.
10. Imrie K, Esmail R, Meyer RM. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 2002; 136: 619-629.
11. Siegel D, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-54.
12. Avet-Loiseau H, Facon T, Grosbois B, Mangrageas F, Rapp MJ, Harousseau JL et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185-2191.
13. Fassas A, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041-1047.
14. Nilsson T, Lenhoff S, Turesson I, Rylander L, Mitelman F, Westin J et al. Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation. Eur J Haematol 2002; 68: 345-353.
15. Palumbo A, Pileri A, Triolo S, Omede P, Bruno B, Ciravegna G et al. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant 1997; 19: 23-29.
16. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
17. Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Hoffbrand AV, Brown MC, Hirsch J (eds). Recent Advances in Haematology. Edinburgh: Churchill Livingstone, 1977, pp 243-261.
18. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842-854.
19. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
20. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remission in multiple myeloma: the role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208-215.
21. Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma : an Italian Multicenter Study. Haematologica 2000; 85: 52-58.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Phil D et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med 2003; 348: 1875-1883.
24. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroup Francophone du myélome 9502 randomized trial. Blood 2002; 99: 731-735.
25. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-342.
26. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GEG et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144-2151.
27. Ries L, Hankey BL, Miller BA. Cancer Statistic Review, 1973-1988 (DHHS publ-NIH-n.91-2789). Washington, DC: US Govt Printing Office, 1991.
28. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Blood 2000; 25: 533-539.